Paper36933835
A novel anti-HBV agent, E-CFCP, restores Hepatitis B virus (HBV)-induced senescence-associated cellular marker perturbation in human hepatocytes.
Takamatsu Y and 6 others. Virus Res, 2023. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. A novel anti-HBV agent, E-CFCP, restores Hepatitis B virus (HBV)-induced senescence-associated cellular marker perturbation in human hepatocytes. Papers, record 36933835. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36933835
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A novel anti-HBV agent, E-CFCP, restores Hepatitis B virus (HBV)-induced senescence-associated cellular marker perturbation in human hepatocytes.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hepatitis B, Chronic | Major topic |
| Hepatitis B | Major topic |
| Humans | |
| Mice | |
| Animals | |
| Hepatitis B virus | |
| Hepatocytes |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| ZIABC011486 | NIH |
Source NIH RePORTER
References64
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27100145 | Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. | Hepatology | 2016 | https://conductscience.org/library/papers/27100145 | PubMed |
| 2 | 33734564 | The struggle of a good friend getting old: cellular senescence in viral responses and therapy. | EMBO Rep | 2021 | https://conductscience.org/library/papers/33734564 | PubMed |
| 3 | 31319796 | HBV-related hepatocarcinogenesis: the role of signalling pathways and innovative ex vivo research models. | BMC Cancer | 2019 | https://conductscience.org/library/papers/31319796 | PubMed |
| 4 | 19656618 | Hepatitis B virus X protein overcomes stress-induced premature senescence by repressing p16(INK4a) expression via DNA methylation. | Cancer Lett | 2010 | https://conductscience.org/library/papers/19656618 | PubMed |
| 5 | 17512084 | Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: factors contributing to hepatocarcinogenesis. | J Hepatol | 2007 | https://conductscience.org/library/papers/17512084 | PubMed |
| 6 | 35851277 | Hepatocyte growth factor derived from senescent cells attenuates cell competition-induced apical elimination of oncogenic cells. | Nat Commun | 2022 | https://conductscience.org/library/papers/35851277 | PubMed |
| 7 | 33999179 | Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. | J Infect Dis | 2021 | https://conductscience.org/library/papers/33999179 | PubMed |
| 8 | 11679961 | Hepatitis B virus X protein increases expression of p21(Cip-1/WAF1/MDA6) and p27(Kip-1) in primary mouse hepatocytes, leading to reduced cell cycle progression. | Hepatology | 2001 | https://conductscience.org/library/papers/11679961 | PubMed |
| 9 | 29608137 | Mechanisms and functions of cellular senescence. | J Clin Invest | 2018 | https://conductscience.org/library/papers/29608137 | PubMed |
| 10 | 36152762 | Reverse inflammaging: Long-term effects of HCV cure on biological age. | J Hepatol | 2023 | https://conductscience.org/library/papers/36152762 | PubMed |
| 11 | 15331414 | Near completely humanized liver in mice shows human-type metabolic responses to drugs. | Am J Pathol | 2004 | https://conductscience.org/library/papers/15331414 | PubMed |
| 12 | 33333207 | Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV. | J Hepatol | 2021 | https://conductscience.org/library/papers/33333207 | PubMed |
| 13 | 33715896 | Is there any need for new, long-acting nucleos(t)ide analogues for the treatment of hepatitis B infection? | J Hepatol | 2021 | https://conductscience.org/library/papers/33715896 | PubMed |
| 14 | 35171034 | Long-Term Hepatitis B Virus Infection Induces Cytopathic Effects in Primary Human Hepatocytes, and Can Be Partially Reversed by Antiviral Therapy. | Microbiol Spectr | 2022 | https://conductscience.org/library/papers/35171034 | PubMed |
| 15 | 31675495 | Cellular Senescence: Defining a Path Forward. | Cell | 2019 | https://conductscience.org/library/papers/31675495 | PubMed |
| 16 | 35576953 | Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. | Lancet Gastroenterol Hepatol | 2022 | https://conductscience.org/library/papers/35576953 | PubMed |
| 17 | 35430754 | Precision medicine in the era of potent antiviral therapy for chronic hepatitis B. | J Gastroenterol Hepatol | 2022 | https://conductscience.org/library/papers/35430754 | PubMed |
| 18 | 34818068 | Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. | J Virol | 2022 | https://conductscience.org/library/papers/34818068 | PubMed |
| 19 | 34517409 | Virus-induced senescence is a driver and therapeutic target in COVID-19. | Nature | 2021 | https://conductscience.org/library/papers/34517409 | PubMed |
| 20 | 29477613 | Hallmarks of Cellular Senescence. | Trends Cell Biol | 2018 | https://conductscience.org/library/papers/29477613 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41613597 | Current status and challenges of therapeutic targets, novel drugs and delivery systems for hepatitis B: how far to our goal? | Front Cell Infect Microbiol | 2025 | https://conductscience.org/library/papers/41613597 | PubMed |
| 41521283 | Mitochondria-endoplasmic reticulum contact sites in hepatocytic senescence. | Cell Mol Biol Lett | 2026 | https://conductscience.org/library/papers/41521283 | PubMed |
| 39831159 | An orally available P1'-5-fluorinated Mpro inhibitor blocks SARS-CoV-2 replication without booster and exhibits high genetic barrier. | PNAS Nexus | 2025 | https://conductscience.org/library/papers/39831159 | PubMed |
| 38977798 | Deviated binding of anti-HBV nucleoside analog E-CFCP-TP to the reverse transcriptase active site attenuates the effect of drug-resistant mutations. | Sci Rep | 2024 | https://conductscience.org/library/papers/38977798 | PubMed |
| 37753486 | Contribution of viral and bacterial infections to senescence and immunosenescence. | Front Cell Infect Microbiol | 2023 | https://conductscience.org/library/papers/37753486 | PubMed |
Genes21
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36933835
GET https://conductscience.org/api/papers/v1/36933835/references?page=2